WP
SUPN icon

WealthPLAN Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

WealthPLAN Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2
Closed -$60 – 1064
2023
Q2 		$60 Hold
2
– – ﹤0.01% 1241
2023
Q1 		$72 Buy
+2
New +$77 ﹤0.01% 1297

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

WealthPLAN Partners's SUPN Position: Q3 2023 in Review

WealthPLAN Partners sold out of Supernus Pharmaceuticals (SUPN) in Q3 2023, closing a stake of 2 shares — an estimated $60 sold.

WealthPLAN Partners first reported a position in SUPN in Q1 2023 and held it in 2 quarters. The position peaked at $72 in Q1 2023. 237 funds tracked by Wall St. Rank hold SUPN as of Q3 2023.

  • WealthPLAN Partners reported no remaining Supernus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • WealthPLAN Partners sold 2 Supernus Pharmaceuticals shares in Q3 2023, an estimated $60.
  • WealthPLAN Partners first reported a position in Supernus Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • WealthPLAN Partners's Supernus Pharmaceuticals position peaked at $72 in Q1 2023.
  • 237 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2023.

Based on WealthPLAN Partners's 13F filing for Q3 2023, filed 2 Nov 2023.